MICA/MICB-Mediated NKG2D Immune Escape in Cervical Cancer: Single-Cell Transcriptomic Mapping of Radionuclide Therapy

Jinchuan Ci1, Chen Wang2, Yuli Wang1

  • 1Dong'e Ejiao Co., Ltd., Shandong Key Laboratory of Gelatine Medicines Research and Development, Liaocheng City, Shandong Province, China.

Abstract

Insights

Cervical cancer

Area of Science:

  • Immunology
  • Oncology
  • Radiochemistry

Background:

  • Cervical cancer exhibits an immunosuppressive tumor microenvironment (TME) hindering anti-tumor immunity and radioimmunotherapy (RNT).
  • The NKG2D receptor-ligand axis (MICA/MICB) is crucial for innate immunity and RNT targetability, but its dysregulation in cervical cancer is poorly understood.

Purpose of the Study:

  • To map the NKG2D-axis immune escape landscape in cervical cancer using single-cell RNA sequencing (scRNA-seq).
  • To assess the translational significance of NKG2D ligand expression for precision RNT target selection and patient stratification.

Main Methods:

  • scRNA-seq analysis of cervical cancer datasets for immune cell profiling and target density assessment.
  • Quantitative PCR and ELISA to measure MICA, MICB, and SUSD1 expression in cervical cancer cell lines.
  • Bioinformatic analysis including Harmony integration and Louvain clustering for cell-type annotation.

Main Results:

  • Cervical cancer TME shows depleted CD8+ T and NK cells, with increased regulatory T cells, creating an RNT-unfavorable environment.
  • Significant downregulation of MICA/MICB and upregulation of SUSD1 were observed, correlating with reduced RNT efficacy.
  • Transcriptomic profiling demonstrated a reliable proxy for estimating theranostic target protein density.

Conclusions:

  • MICA/MICB downregulation and SUSD1 upregulation suppress NKG2D-mediated immunity, leading to an immune-cold TME limiting RNT efficacy.
  • A precision RNT strategy involves scRNA-seq guided patient stratification and theranostic imaging.
  • Combination radioimmunotherapy with MICA/MICB re-expression induction offers a novel approach for targeting NKG2D-ligand-negative tumors.